Researchers with Massachusetts General Hospital have identified some crosstalk communication between TREM2 and CD33, two genes that play a role in inflammation and Alzheimer’s disease.
Older adults with slightly elevated blood sugar – sometimes called “prediabetes” – usually do not develop full-blown diabetes, a Swedish study suggests.
People who track their daily steps may not only be more active, they may also be less likely to develop health problems that lead to events like heart attacks or broken bones, a new study suggests.
Concern about clinical trial transparency, or more accurately the lack of transparency, is an ongoing problem. A new report shows that the lack of transparency also extends to post-marketing commitments that companies agreed to, following regulatory approval of a drug.
Researchers have harnessed the power of social media to build a genetic database, according to a new report.
In 2015, Pfizer researchers were analyzing hundreds of thousands of insurance claims and noted that patients receiving the company’s anti-inflammatory Enbrel appeared to have a reduced risk of Alzheimer’s disease – by a startling 64 percent.
Cancer drug study patients tend to be younger than most people with the disease in the general population.
Emory University in Georgia fired a husband and wife neuroscience research team after they were accused of failing to disclose ties to China that included financial funding.
FDA Approves NovoTTF-100L for Mesothelioma Therapy
Approvals, Asbestos, Cancer, Cancer Cells, Carcinogens, Chemotherapy, FDA, FDA/Regulatory, Hormone Therapy, Immunotherapies, Lungs, Malignant Pleural Mesothelioma, Medical Devices, Mesothelioma, Photodynamic therapy, Researchers, Tumor Treating Fields (TTF)The NovoTTF-100L therapy has become an FDA-approved therapy that is helping improve the lives of mesothelioma patients.
Boehringer Ingelheim Lands Positive Results in Lung Disease Trial
Clinical Trials, Connective Tissue, Data, European Medicines Agency, FDA, Idiopathic Pulmonary Fibrosis, merican Thoracic Society (ATS) International Conference, Priority Review Status, R&D, Researchers, Scleroderma, Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD), The New England Journal of Medicine (NEJM)Boehringer Ingelheim’s SENSCIS Phase III clinical trial met the primary endpoint for nintedanib in patients with SSc-ILD.